Ranked #3,275 of 8,699 institutional investors
Octagon Capital Advisors LP
New York, NY
$591M
US stock portfolio at live prices · today −$19.6M (−3.20%)
Live prices, last trade 11:29 AM ET
- Value at quarter end (Q3 2026)
- $740M
- Change from Q2 2026
- −$349.5M (−32.08%)
- Positions
- 24 · 2 new, 3 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: call options on $10.6M of stock. $7.9M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesDNTH 23.9%DFTX 12.4%ABVX 11.6%COGT 10.7%TSHA 6.12%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| DNTH Dianthus Therapeutics, Inc. | 1,686,667 | $141M | 23.9% | Reduced −8% |
| DFTX Definium Therapeutics, Inc. | 2,511,000 | $73.1M | 12.4% | Reduced −15% |
| ABVX ABIVAX Société Anonyme | 993,000 | $68.6M | 11.6% | Unchanged |
| COGT Cogent Biosciences, Inc. | 2,350,000 | $63.3M | 10.7% | Unchanged |
| TSHA Taysha Gene Therapies, Inc. | 9,693,244 | $36.2M | 6.12% | Unchanged |
| OBX Obsidian Therapeutics, Inc. | 2,414,610 | $28.8M | 4.88% | New |
| KYMR Kymera Therapeutics, Inc. | 205,000 | $23.7M | 4.01% | Reduced −34% |
| AVBP ArriVent BioPharma, Inc. | 2,141,387 | $23.5M | 3.98% | Added +9% |
| IRON Disc Medicine, Inc. | 270,000 | $20.2M | 3.42% | Unchanged |
| MIRM Mirum Pharmaceuticals, Inc. | 169,450 | $16.6M | 2.81% | Reduced −50% |
| XENE Xenon Pharmaceuticals Inc. | 420,000 | $15.7M | 2.65% | Reduced −14% |
| TNGX Tango Therapeutics, Inc. | 630,000 | $14.1M | 2.39% | New |
| AKTS Aktis Oncology, Inc. | 713,000 | $11.7M | 1.97% | Reduced −26% |
| PALI Palisade Bio, Inc. | 10,276,317 | $9.6M | 1.62% | Unchanged |
| ANL Adlai Nortye Group Ltd. | 934,716 | $8.1M | 1.36% | Unchanged |
| BIOA BioAge Labs, Inc. | 1,300,000 | $5.8M | 0.99% | Reduced −26% |
| DBVT DBV Technologies S.A. | 574,200 | $5.3M | 0.89% | Unchanged |
| TRVI Trevi Therapeutics, Inc. | 315,000 | $4.2M | 0.71% | Unchanged |
| GYRE Gyre Therapeutics, Inc. | 954,416 | $4.1M | 0.69% | Unchanged |
| OCUL Ocular Therapeutix, Inc. | 599,900 | $3.4M | 0.58% | Reduced −71% |
| DTIL Precision BioSciences, Inc. | 430,000 | $3.1M | 0.53% | Reduced −68% |
| GOSS Gossamer Bio, Inc. | 96,875 | $1.1M | 0.19% | Unchanged |
| UNCY Unicycive Therapeutics, Inc. | 275,000 | $965K | 0.16% | Reduced −73% |
| FTH Faeth Therapeutics, Inc. | 100,000 | $865K | 0.15% | Reduced −72% |